JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE ›› 2026, Vol. 28 ›› Issue (5): 853-862.DOI: 10.3969/j.issn.1671-2587.2026.05.025
Previous Articles Next Articles
CAO Bowei, CHENG Hong, LI Dandan, WANG Zhicheng
Received:2026-09-02
Revised:2026-09-23
Online:2026-10-20
Published:2026-11-11
CLC Number:
CAO Bowei, CHENG Hong, LI Dandan, WANG Zhicheng. Advances in Individual Variability in Platelet ABH Antigen Expression and Its Functional Implications for Transfusion Medicine[J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2026, 28(5): 853-862.
Add to citation manager EndNote|Ris|BibTeX
URL: http://www.lcsxyjy.com/EN/10.3969/j.issn.1671-2587.2026.05.025
| [1] Lee-Sundlov M M,Stowell S R,Hoffmeister K M. Multifaceted role of glycosylation in transfusion medicine, platelets,and red blood cells[J]. J Thromb Haemost,2020, 18(7):1535-1547. [2] Ward S E,O'Sullivan J M,O'Donnell J S. The relationship between ABO blood group,von Willebrand factor,and primary hemostasis[J]. Blood,2020,136(25):2864-2874. [3] Cain L,Aggarwal A,Geneen L J,et al.ABO matching for platelet transfusions for prevention or treatment of bleeding: A systematic review with meta-analysis[J]. Transfus Med Rev,2026,40(1):150928. [4] Jajosky R P,Wu S C,Zheng L,et al.ABO blood group antigens and differential glycan expression: Perspective on the evolution of common human enzyme deficiencies[J]. iScience,2023,26(1):105798. [5] Mollicone R,Caillard T,Le Pendu J,et al.Expression of ABH and X (Lex) antigens on platelets and lymphocytes[J]. Blood,1988,71(4):1113-1119. [6] Holgersson J,Breimer M E,Jacobsson A,et al.Glycolipid- and glycoprotein-based blood group A antigen expression in human thrombocytes. A1/A2 difference[J]. Glycoconj J, 1990,7(6):601-608. [7] Santoso S,Kiefel V,Mueller-Eckhardt C.Blood group a and B determinants are expressed on platelet glycoproteins Ⅱa,Ⅲa,and ⅰb[J]. Thromb Haemost,1991,65(2):196-201. [8] Hou M,Stockelberg D,Rydberg L,et al.Blood group A antigen expression in platelets is prominently associated with glycoprotein Ⅰb and Ⅱb. Evidence for an A1/A2 difference[J]. Transfus Med,1996,6(1):51-59. [9] Kelton J G,Smith J W,Horsewood P,et al.ABH antigens on human platelets: expression on the glycosyl phosphatidylinositol-anchored protein CD109[J]. J Lab Clin Med,1998,132(2):142-148. [10] Hollenhorst M A,Tiemeyer K H,Mahoney K E, et al.Comprehensive analysis of platelet glycoprotein Ibα ectodomain glycosylation[J]. J Thromb Haemost,2023, 21(4):995-1009. [11] Skogen B,Rossebø Hansen B,Husebekk A,et al.Minimal expression of blood group A antigen on thrombocytes from A2 individuals[J]. Transfusion,1988,28(5):456-459. [12] Cooling L L,Kelly K,Barton J,et al.Determinants of ABH expression on human blood platelets[J]. Blood, 2005,105(8):3356-3364. [13] Dunstan R A,Simpson M B,Knowles R W,et al.The origin of ABH antigens on human platelets[J]. Blood, 1985,65(3):615-619. [14] Ogasawara K,Ueki J,Takenaka M,et al.Study on the expression of ABH antigens on platelets[J]. Blood,1993,82(3):993-999. [15] Curtis B R,Edwards J T,Hessner M J,et al.Blood group A and B antigens are strongly expressed on platelets of some individuals[J]. Blood,2000,96(4):1574-1581. [16] O'Donghaile D,Jenkins P V,McGrath R T,et al. Expresser phenotype determines ABO(H) blood group antigen loading on platelets and von Willebrand factor[J]. Sci Rep,2020,10(1):18366. [17] Hindle M S,Cheah L T,Yates D M,et al.Preanalytical conditions for multiparameter platelet flow cytometry[J]. Res Pract Thromb Haemost,2023,7(7):102205. [18] Canis K,McKinnon T A,Nowak A,et al. Mapping the N-glycome of human von willebrand factor[J]. Biochem J,2012,447(2):217-228. [19] Ward S,O'Sullivan J M,O'Donnell J S. The biological significance of von willebrand factor O-linked glycosylation[J]. Semin Thromb Hemost,2021,47(7):855-861. [20] Swystun L L,Lillicrap D.Genetic regulation of plasma von Willebrand factor levels in health and disease[J]. J Thromb Haemost,2018,16(12):2375-2390. [21] Ward S,O'Sullivan J M,O'Donnell J S. Von Willebrand factor sialylation-a critical regulator of biological function[J]. J Thromb Haemost,2019,17(7):1018-1029. [22] Murray G P,Post S R,Post G R.ABO blood group is a determinant of von Willebrand factor protein levels in human pulmonary endothelial cells[J]. J Clin Pathol,2020, 73(6):347-349. [23] Dunne E,Qi Q M,Shaqfeh E S,et al.Blood group alters platelet binding kinetics to von Willebrand factor and consequently platelet function[J]. Blood,2019,133(12): 1371-1377. [24] Nowak A A,Canis K,Riddell A,et al.O-linked glycosylation of von Willebrand factor modulates the interaction with platelet receptor glycoprotein Ib under static and shear stress conditions[J]. Blood,2012,120(1): 214-222. [25] Bonazza K,Iacob R E,Hudson N E,et al.Von Willebrand factor A1 domain stability and affinity for GPⅠbα are differentially regulated by its [26] Cao Y W,Zhang X F,Im W.Dynamics of a von willebrand factor A1 autoinhibitory module with O-linked glycans and its roles in regulation of GPⅠbα binding[J]. J Phys Chem B,2025,129(15):3796-3806. [27] Refaai M A,Henrichs K F,Spinelli S L,et al.Platelet activation following exposure to anti-ABO antibodies-an [28] Refaai M A,Carter J,Henrichs K F,et al.Alterations of platelet function and clot formation kinetics after [29] Dunbar N M.Does ABO and RhD matching matter for platelet transfusion?[J]. Hematology Am Soc Hematol Educ Program,2020,2020(1):512-517. [30] Heal J M,Rowe J M,McMican A,et al. The role of ABO matching in platelet transfusion[J]. European J Haematology,1993,50(2):110-117. [31] Pandey P,Kumari S,Mandal S,et al.A prospective observational study to compare transfusion outcomes in ABO identical versus ABO non-identical single donor platelet concentrates: An experience from a tertiary healthcare center in India[J]. Transfus Clin Biol,2022, 29(3):213-218. [32] Das N,Prakash S,Sahu A,et al.Impact of dose and storage duration of platelet concentrates on platelet recovery between ABO identical and ABO non-identical random donor platelet transfusions in hemato-oncology patients[J]. Hematol Transfus Cell Ther,2024,46(3):228-236. [33] Bougie D W,Reese S E,Birch R J,et al.Associations between ABO non-identical platelet transfusions and patient outcomes-a multicenter retrospective analysis[J]. Transfusion,2023,63(5):960-972. [34] Magid-Bernstein J,Beaman C B,Carvalho-Poyraz F, et al.Impacts of ABO-incompatible platelet transfusions on platelet recovery and outcomes after intracerebral hemorrhage[J]. Blood,2021,137(19):2699-2703. [35] Dunn L K,Venner E,Nguyen M,et al.ABO-identical versus incompatible platelet transfusion in patients with intracranial hemorrhage[J]. PLoS One,2024,19(11): e0312602. [36] Yildiz A,Yaman S,Çiftçiler R,et al.Safety of ABO-incompatible platelet transfusions: a multicenter retrospective cohort study[J]. J Patient Saf,2026,22(4):296-299. [37] Blumberg N,Heal J M,Hicks G L Jr,et al. Association of ABO-mismatched platelet transfusions with morbidity and mortality in cardiac surgery[J]. Transfusion,2001, 41(6):790-793. [38] Zulkeflee R H,Hassan M N,Hassan R,et al.Acute hemolytic transfusion reaction following ABO-mismatched platelet transfusion: Two case reports[J]. Transfus Apher Sci,2023,62(3):103658. [39] Bienz M,Gupta A,Goldstein J,et al.Severe acute haemolytic transfusion reaction secondary to a plasma incompatible group B platelet transfusion[J]. Transfus Med,2023,33(2):188-193. [40] Augustine M,Murugesan M,Gopakumar K G,et al.Case report and strategies to mitigate passive hemolysis with platelet transfusions in children[J]. Asian J Transfus Sci, 2021,15(2):229-232. [41] Gehrie E A,Savani B N,Booth G S.Risk factors for hemolytic transfusion reactions resulting from ABO and minor red cell antigen incompatibility: From mislabeled samples to stem cell transplant and sickle cell disease[J]. Blood Rev,2021,45:100719. [42] Malvik N,Leon J,Schlueter A J,et al.ABO-incompatible platelets are associated with increased transfusion reaction rates[J]. Transfusion,2020,60(2):285-293. [43] Hogan K O,Mudunkotuwa G,Phadnis M,et al.ABO incompatibility and component irradiation are independently associated with platelet transfusion reaction rate[J]. Transfusion,2025,65(3):496-504. [44] Aguilar G,Ortiz N,Gonzales D,et al.High titers of anti-A1 and anti-B antibodies among Peruvian group O platelet donors[J]. Transfus Apher Sci,2022,61(3):103341. [45] Hua Q Y,Lyon B W,Duke J,et al.Isohemagglutinin titration in pooled and apheresis platelets[J]. Transfusion, 2024,64(7):1279-1286. [46] Murugesan M,Augustine M,Velayudhan S C,et al.Hemolysin test as a tool to screen high-titer Group O platelet apheresis donors: A prospective study[J]. Asian J Transfus Sci,2023,17(2):189-194. [47] Bastos E P,Castilho L,Bub C B,et al.Comparison of ABO antibody titration,IgG subclasses and qualitative haemolysin test to reduce the risk of passive haemolysis associated with platelet transfusion[J]. Transfus Med, 2020,30(4):317-323. [48] Weisberg S P,Shaz B H,Tumer G,et al.PAS-C platelets contain less plasma protein,lower anti-A and anti-B titers, and decreased HLA antibody specificities compared to plasma platelets[J]. Transfusion,2018,58(4):891-895. [49] Pagano M B,Katchatag B L,Khoobyari S,et al.Evaluating safety and cost-effectiveness of platelets stored in additive solution (PAS-F) as a hemolysis risk mitigation strategy[J]. Transfusion,2019,59(4):1246-1251. [50] Adzahar S,Hassan M N,Zulkafli Z,et al.Platelet additive solutions as an alternative storage medium of apheresis platelets to reduce ABO antibody titer for ABO-incompatibility platelet transfusion[J]. Cureus,2023,15(8): e44012. [51] Jung Y,Luo O,Sen N N,et al.The safety of ABO minor incompatible platelets transfusions using a rapid infuser[J]. Transfusion,2024,64(3):449-453. [52] Cohn C S.Platelet transfusion refractoriness: how do I diagnose and manage?[J]. Hematology Am Soc Hematol Educ Program,2020,2020(1):527-532. [53] 中华医学会血液学分会. 血小板无效输注诊断和治疗中国专家共识(2022年版)[J]. 中华血液学杂志,2022, 43(11):897-902. [54] Matsui R,Hagino T,Tsuno N H,et al.Does time of CCI measurement affect the evaluation of platelet transfusion effectiveness?[J]. Transfus Apher Sci,2021,60(3):103123. [55] Belizaire R,Makar R S.Non-alloimmune mechanisms of thrombocytopenia and refractoriness to platelet transfusion[J]. Transfus Med Rev,2020,34(4):242-249. [56] Blandin L,Dougé A,Fayard A,et al.Platelet transfusion refractoriness and anti-HLA immunization[J]. Transfusion, 2021,61(6):1700-1704. [57] Arabi S,Almahayni A O,Alomair A A,et al.Prevalence, risk factors,and outcomes of platelet transfusion refractoriness in critically ill patients: a retrospective cohort study[J]. Crit Care Res Pract,2021,2021: 5589768. [58] Han M H,Badami K G.ABO non-identical platelet transfusions,immune platelet refractoriness and platelet support[J]. Br J Haematol,2024,204(5):2097-2102. [59] Gammon R,Mo A.The importance of ABO in platelet refractoriness,an often overlooked option[J]. Br J Haematol,2024,204(5):1602-1604. [60] Garraud O,Hamzeh-Cognasse H,Chalayer E,et al.Platelet transfusion in adults: An update[J]. Transfus Clin Biologique,2023,30(1):147-165. [61] McCullagh J,Cardigan R,Brunskill S J,et al. Assessing the risks of haemolysis as an adverse reaction following the transfusion of ABO incompatible plasma-containing components - A scoping review[J]. Blood Rev,2022,56: 100989. [62] Shen C Y,Bengtsson J,Jöud M,et al.When is ABO-incompatible plasma safe to transfuse? Defining an empirical estimation of anti-A/anti-B in ABO incompatible plasma-containing blood products[J]. Blood Transfus, 2025,23(5):393-408. [63] Andreu G,Boudjedir K,Meyer N,et al.Platelet additive solutions and pathogen reduction impact on transfusion safety,patient management and platelet supply[J]. Transfus Med Rev,2025,39(1):150875. [64] Yıldız A,Doğan M,Yalvaç M,et al.Platelet inventory and using out-of-group platelet suspension: a cost-effective strategy for a blood transfusion service[J]. Hematol Oncol Stem Cell Ther,2023,16(4):337-341. |
| [1] | NIU Lei, MA Chunya, YANG Wei, FU Fanfan, XU Tingchen, ZHANG Xin, YU Yang. Study on Two Platelet Transfusion Strategies of Minimal Mismatch and Random Transfusion and Their Effects [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2026, 28(5): 705-711. |
| [2] | ZHANG Li, YI Hai, MA Lei, GAN Xinyu, LIU Liping, QI Yu, TAN Qiang, LI Huan, REN Lina, PENG Tao. The Influence of Preparation Methods on the Efficacy and Safety of Recombinant Apheresis Platelet Transfusion [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2026, 28(5): 717-725. |
| [3] | ZHI Yuan, ZHANG Chun, WANG Na, ZHANG Yu, LING Yating, FU Qiang, HE Chengtao. Characterization of High-abundance Intact Glycopeptides in Platelets [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2026, 28(4): 518-524. |
| [4] | YANG Ying, QIAN Chengrui, LI Qin, GUO Zhonghui, ZHAO Fengyong, ZHANG Jiamin, YANG Qixiu, WANG Chen, ZHU Ziyan. Heterogeneous Effects of Anti-PF4 Antibodies on Platelet Function in Patients with Thrombocytopenia [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2026, 28(4): 546-552. |
| [5] | WANG Xin, LI Yao, SHAN Zhuoyue, ZHAO Liyan. Research Progress on the Relationship between CD36 Antigen Deficiency and Clinical Blood Transfusion Safety [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2026, 28(2): 279-285. |
| [6] | LIU Wen, WANG Wenxing, FAN Na, CHEN Wei, LIANG Jing. Imbalance between Th17/Treg Cells and Associated Cytokines in Patients with Platelet Transfusion Refractoriness [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2026, 28(1): 65-69. |
| [7] | CAI Xiaohong, LEI Hang, WANG Xuefeng. 2025 AABB and ICTMG International Clinical Practice Guidelines—Guidelines for Platelet Transfusion and Key Points Interpretation [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2025, 27(5): 577-584. |
| [8] | HE Ziyi, HU Yingming, BEI Menghui, LIU Jing, JIE Xiaomei, CHEN Shaobin, ZHONG Chihui, LIANG Huaqin. Establishment and Analysis of the Database of CD36 Antigen-deficient Platelet Donors in Dongguan [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2025, 27(4): 492-498. |
| [9] | ZHAO Han, PEI Renjun, WANG Caixian, DU Xi, LI Xiaoyue, JIANG Peng, LIN Fangzhao, SUN Pan, CAO Haijun. Changes of Main Functional Components of Human Plasma-derived Factor Ⅷ Products in China in Recent Years [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2025, 27(3): 360-367. |
| [10] | SUN Yang, NIU Jiameng, XING Lili, MA Ting, DU Gongliang, LI Xuewen, WANG Yaqin, WANG Liqin, CHEN Ping, WANG Wenhua, YANG Yingqun, SONG Aowei, XIE Xinxin, SONG Yaojun, WANG Miaoni, CHANG Jingyan, TIAN Fenfang, YANG Jiangcun. The Clinical Efficacy of 4 ℃ Stored Platelet: a Randomized Controlled Feasibility Trial Conducted in Surgical Patients with Hemorrhage [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2025, 27(2): 145-155. |
| [11] | LIU Zhen, TANG Longhai, JIN Yiming, XU Zihao, WANG Mingyuan. Experimental Study on the Effects of Smoking on Platelet Count and Activation Function [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2025, 27(1): 29-33. |
| [12] | MA Xiaojie, CHEN Wei. Potential Biomarkers Related to Venous Thromboembolism: Current Research Trends [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2025, 27(1): 135-139. |
| [13] | FAN Chengyan, WEN Yujie, LIAN Xue, ZHANG Dan, WANG Jie, JING Yuanyuan, WANG Lijun, LI Wei, JIA Yanjun, LI Dongmei. Changes in Serum Platelet-related Antibodies in Patients with Immune Platelet Transfusion Refractoriness and Clinical Significance [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(5): 661-666. |
| [14] | ZHAO Jialu, FAN Xinqiu, ZENG Yimei, CAI Xiaohong, LI Jiaming, WANG Xuefeng. Clinical Characteristics and Correlation Analysis of Platelet Transfusion Refractoriness in Patients with TUBB1 Mutant Myelodysplastic Syndrome [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(5): 683-689. |
| [15] | QIAO Mingming, Gongjuedunzhu, CHEN Yuanfeng, YU Yuan, YE Hui, ZHUANG Yunlong. Effect of 4 ℃ Cold-Stored Platelets Transfusion on Acute Renal Injury Induced by Hemorrhagic Shock in Rats [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(4): 470-474. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
